- Trastuzumab emtansine (also known as T-DM1) is an antibody-drug conjugate (ADC) combining the HER2-targeted antitumor properties of trastuzumab with the cytotoxic agent DM1. It is primarily used in the treatment of HER2-positive metastatic breast cancer, especially in patients who have previously received trastuzumab and a taxane
- The global trastuzumab emtansine market is witnessing significant growth due to the increasing incidence of HER2-positive breast cancer and rising demand for targeted therapies. Market expansion is further supported by ongoing clinical trials evaluating T-DM1 in earlier treatment lines and other HER2-positive cancers. High treatment efficacy and improved patient outcomes compared to traditional chemotherapy options drive adoption
- North America is expected to dominate the trastuzumab emtansine market with a market share of approximately 41.2% in 2025, driven by the high incidence of HER2-positive breast cancer, early adoption of antibody-drug conjugates (ADCs), and strong presence of key pharmaceutical companies such as Genentech (Roche) and ImmunoGen.
- Asia-Pacific is expected to be the fastest growing region in the global trastuzumab emtansine market, with a projected market share of approximately 25.7% in 2025, driven by the rising prevalence of HER2-positive breast cancer, increased awareness of targeted cancer therapies, and the growing accessibility of biologics in emerging economies
- Breast cancer segment is expected to dominate the market with a market share of 90.7% in 2025 due to its widespread use in the treatment of HER2-positive metastatic and early-stage breast cancer. As a targeted antibody-drug conjugate, trastuzumab emtansine has demonstrated strong clinical efficacy in improving progression-free and overall survival among breast cancer patients, especially those resistant to prior HER2 therapies
